BACKGROUND: Retrospective and molecular biologic data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC). PATIENTS AND METHODS: Eligibility criteria included advanced nccRCC except for collecting duct carcinoma and sarcomatoid carcinoma without identifiable renal cell carcinoma subtypes. Patients were treated with 50 mg/day oral sunitinib for 4 weeks, followed by 2 weeks of rest. The primary end point was overall response rate (RR). RESULTS: Thirty-one eligible patients were enrolled. Twenty-four patients (77%) had prior nephrectomy. By Memorial Sloan-Kettering Cancer Center criteria, 8 patients (26%) had poor risk and 14 (45%) had intermediate risk. Twenty-two patients had papillary renal cell carcinoma (RCC), and three had chromophobe RCC. Eleven patients had partial response with a RR of 36% (95% confidence interval (CI) 19% to 52%) and an additional 17 patients (55%) had stable disease. Median duration of response was 12.7 months (95% CI 6.3-19.1 months), and median progression-free survival was 6.4 months (95% CI 4.2-8.6 months). At a median follow-up duration of 18.7 months (95% CI 13.7-23.7 months), 13 patients (42%) had died, resulting in an estimated median survival of 25.6 months (95% CI 8.4-42.9 months). Toxicity profiles were commensurate with prior reports. CONCLUSIONS: Sunitinib has promising activity in patients with nccRCC (NCT01219751).
BACKGROUND: Retrospective and molecular biologic data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC). PATIENTS AND METHODS: Eligibility criteria included advanced nccRCC except for collecting duct carcinoma and sarcomatoid carcinoma without identifiable renal cell carcinoma subtypes. Patients were treated with 50 mg/day oral sunitinib for 4 weeks, followed by 2 weeks of rest. The primary end point was overall response rate (RR). RESULTS: Thirty-one eligible patients were enrolled. Twenty-four patients (77%) had prior nephrectomy. By Memorial Sloan-Kettering Cancer Center criteria, 8 patients (26%) had poor risk and 14 (45%) had intermediate risk. Twenty-two patients had papillary renal cell carcinoma (RCC), and three had chromophobe RCC. Eleven patients had partial response with a RR of 36% (95% confidence interval (CI) 19% to 52%) and an additional 17 patients (55%) had stable disease. Median duration of response was 12.7 months (95% CI 6.3-19.1 months), and median progression-free survival was 6.4 months (95% CI 4.2-8.6 months). At a median follow-up duration of 18.7 months (95% CI 13.7-23.7 months), 13 patients (42%) had died, resulting in an estimated median survival of 25.6 months (95% CI 8.4-42.9 months). Toxicity profiles were commensurate with prior reports. CONCLUSIONS:Sunitinib has promising activity in patients with nccRCC (NCT01219751).
Authors: Nizar M Tannir; Elizabeth Plimack; Chaan Ng; Pheroze Tamboli; Nebiyou B Bekele; Lianchun Xiao; Lisa Smith; Zita Lim; Lance Pagliaro; John Araujo; Ana Aparicio; Surena Matin; Christopher G Wood; Eric Jonasch Journal: Eur Urol Date: 2012-06-27 Impact factor: 20.096
Authors: Andrew J Armstrong; Susan Halabi; Tim Eisen; Samuel Broderick; Walter M Stadler; Robert J Jones; Jorge A Garcia; Ulka N Vaishampayan; Joel Picus; Robert E Hawkins; John D Hainsworth; Christian K Kollmannsberger; Theodore F Logan; Igor Puzanov; Lisa M Pickering; Christopher W Ryan; Andrew Protheroe; Christine M Lusk; Sadie Oberg; Daniel J George Journal: Lancet Oncol Date: 2016-01-13 Impact factor: 41.316
Authors: Joshua E Logan; Edward N Rampersaud; Geoffrey A Sonn; Karim Chamie; Arie S Belldegrun; Allan J Pantuck; Dennis J Slamon; Fairooz F Kabbinavar Journal: Rev Urol Date: 2012
Authors: Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri Journal: Eur Urol Date: 2015-11-26 Impact factor: 20.096
Authors: Lauren C Harshman; Nils Kroeger; Sun Young Rha; Frede Donskov; Lori Wood; Srinivas K Tantravahi; Ulka Vaishampayan; Brian I Rini; Jennifer Knox; Scott North; Scott Ernst; Takeshi Yuasa; Sandy Srinivas; Sumanta Pal; Daniel Y Heng; Toni K Choueiri Journal: Clin Genitourin Cancer Date: 2014-03-15 Impact factor: 2.872
Authors: Toni K Choueiri; Ulka Vaishampayan; Jonathan E Rosenberg; Theodore F Logan; Andrea L Harzstark; Ronald M Bukowski; Brian I Rini; Sandy Srinivas; Mark N Stein; Laurel M Adams; Lone H Ottesen; Kevin H Laubscher; Laurie Sherman; David F McDermott; Naomi B Haas; Keith T Flaherty; Robert Ross; Peter Eisenberg; Paul S Meltzer; Maria J Merino; Donald P Bottaro; W Marston Linehan; Ramaprasad Srinivasan Journal: J Clin Oncol Date: 2012-12-03 Impact factor: 44.544
Authors: Jae-Cheol Jo; Yong Sang Hong; Kyu-Pyo Kim; Jae-Lyun Lee; Jeeyun Lee; Young Suk Park; Sun Young Kim; Jin-Sook Ryu; Jong-Seok Lee; Tae Won Kim Journal: Invest New Drugs Date: 2014-01-16 Impact factor: 3.850